Major reasons for the slow uptake of outcomes-based risk-sharing agreements in the U.S. are regulatory issues, operational requirements, and deficits in information sharing, according to a literature review published in JMCP.
This JMCP article describes how the Biosimilars Collective Intelligence Consortium (BBCIC) has the ability to coordinate sophisticated post-approval surveillance of biologics and biosimilars by utilizing its distributed research network.
Digital therapeutics: What are they, and where do they fit into pharmacy and medical benefits? Learn more in this blog post from AMCP CEO Susan A. Cantrell, RPh, CAE.
This JMCP article describes how the Biosimilars Collective Intelligence Consortium (BBCIC) has the ability to coordinate sophisticated post-approval survellience of biologics and biosimilars by utilizing its distributed research network.
Major reasons for the slow uptake of outcomes-based risk-sharing agreements in the U.S. are regulatory issues, operational requirements, and deficits in information sharing, according to a literature review published in JMCP.
AMCP CEO Blog: With PA so often misunderstood, perhaps we need to do a better job of explaining this tool to the general public. For example, we might provide an example of how PAs are applied to opioids as additional safeguards to ensure their appropriate use. Or how a PA might be applied to botulinum toxin to ensure the prescription is for medical, rather than cosmetic, purposes.
By AMCP CEO Susan A. Cantrell, RPh, CAE • 11/13/19